HOME >> BIOLOGY >> NEWS
Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID

Worcester, Mass. June 28, 2007 -- Biovest International, Inc. (OTCBB: BVTI), a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June 27, 2007 blinded interim data from the start of its fast-tracked pivotal Phase 3 clinical trial of BiovaxID for Non-Hodgkins lymphoma (NHL) from September 2000 through June 2006. This interim blinded data is the most recent data that has been made available to the Company prior to its latest meeting with the Data Monitoring Committee for the ongoing Phase 3 study. The interim blinded data covers 122 patients who have received either BiovaxID or control vaccine. Randomization was 2:1 in favor of BiovaxID. The blinded data in a Kaplan Meier disease-free survival curve for the per-protocol treatment group in the trial showed that approximately 40% of the evaluable patients in the study remained disease-free from 40 months to almost 70 months.

Dr. Steve Arikian, Biovest Chairman and Chief Executive Officer, stated, Biovest believes these results are consistent with the expected efficacy of BiovaxID vs. control. Moreover, BiovaxID has the longest Phase 3 follow-up data for patients receiving an active immunotherapy for follicular Non-Hodgkins Lymphoma of any of the Phase 3 Non-Hodgkins Lymphoma immunotherapy trials ongoing today. We are greatly encouraged by the blinded interim data presented at the Jeffries Healthcare Conference on June 27th, 2007.

BiovaxID is an anti-cancer vaccine undergoing testing in a Fast-Tracked pivotal Phase 3 clinical trial for a target indication of Non-Hodgkins Lymphoma. BiovaxID is a personalized, patient-specific vaccine designed to stimulate the patients own immune system to recognize and destroy residual cancerous B-cells that remain after the patient has undergone chemotherapy. Unlike many other approaches to treating NHL, BiovaxID is designed to target only cancerous B-cells. The BiovaxID Phase 3 clinical trial is being conducted at
'"/>

Contact: Adam Holdsworth
aholdsworth@investorrelationsgroup.com
212-825-3210
The Investor Relations Group
28-Jun-2007


Page: 1 2

Related biology news :

1. Biovest International submits amendment request to FDA for use of molecular remission data
2. AutovaxID-C introduced by Biovest International
3. Biovest International announces that it will report new follow-up data
4. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
5. ESA announces 2007 award recipients
6. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology
7. Conservation Leadership Program announces 2007 awardees
8. ACMG Foundation announces 2007-2008 Luminex/ACMGF award recipient
9. Revolutionary global environment fund announces $50M expansion
10. Cell Press announces new partnership with the American Society of Human Genetics
11. ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/7/2020)... ... 2020 , ... Nine middle school teachers from eight states ... unique professional development program that provides advanced STEM (science, technology, engineering and math) ... , Created in partnership between the National Stem Cell Foundation and The Gatton ...
(Date:7/31/2020)... ... July 30, 2020 , ... Justin Zamirowski to lead ... near term focus on Type 2 diabetes and associated comorbidities. , Justin brings ... areas and classes. As Chief Commercial Officer, Justin will lead Better Therapeutics’ ...
(Date:7/10/2020)... ... July 08, 2020 , ... Overcoming Comparability ... Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. EDT, ... is the most effective way to complete one? Will the study comply with ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... 2020 , ... Introducing Ardent Animal Health – MediVet Biologics rebrands company and ... Known as MediVet Biologics since its formation in 2016, the company is relaunching itself ... will build on its base of innovative therapies for osteoarthritis and cancer. ...
(Date:7/31/2020)... ... 29, 2020 , ... Anomet Products has introduced new custom ... use with CRM, neurostimulation, vascular, and related devices. , Anomet Medical Clad ... performance, and cost criteria; especially where solid wire is limited. Typical configurations for ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... software for the life sciences industry, today announced the release of its ... specifically for Medical Science Liaisons (MSLs) and other field medical professionals. ...
(Date:7/18/2020)... ... 2020 , ... Medial EarlySign , a leader in ... high-burden diseases, and Centric Consulting, a business and technology consulting firm, today announced ... in order to identify and prioritize patients for care. , Combining Centric’s management ...
Breaking Biology Technology:
Cached News: